A research team led by Prof. Nie Guangjun from the National Center for Nanoscience and Technology (NCNST) of the Chinese ...

A research team led by Prof. NIE Guangjun from the National Center for Nanoscience and Technology (NCNST) of the Chinese ...

A simultaneous webcast will be available in the Investors section of Replimune’s website at replimune.com. A replay will be available for 30 days following the conference.

A new publication from Genes & Diseases; DOI 10.1016/j.gendis.2024.101441, discusses how Ce6-GFFY is a novel photosensitizer for colorectal cancer therapy.

M shows promise with 55 effectiveness in trials Learn how this breakthrough could revolutionize malaria prevention ...

Project focuses on the development of a mucosal immunization strategy.

Following positive Phase IIb trial results, RH5.1/Matrix-M has the potential to be the first blood-stage malaria vaccine brought to market.

A new publication from Genes & Diseases; DOI 10.1016/j.gendis.2024.101441 , discusses how Ce6-GFFY is a novel photosensitizer for colorectal cancer ...

The first blood-stage malaria vaccine RH5.1/Matrix-M has the potential to be a component within a developing malaria vaccine strategy, said a report on Thursday.

Articles on myeloproliferative neoplasms (MPNs) covered the debate over how early to use cytoreductive therapies instead of ...